GlassScriptPhysician profile
Ranjan Patel Goli
NPI 1043835937
$2,403.97
in general payments reported to CMS, 2019-2025
37 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $400 · 2024: $676 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,403.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $248.99 | 2024-2025 | Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $216.12 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $136.66 | 2024-2025 | |
| Seagen INC. | $130.72 | 2023 | Tukysa, Padcev, Adcetris |
| Daiichi Sankyo INC. | $122.51 | 2024-2025 | Enhertu |
| Incyte Corporation | $117.32 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $113.66 | 2023-2025 | Opdivo, Opdualag, Augtyro |
| Novartis Pharmaceuticals Corporation | $110.47 | 2024-2025 | |
| Abbvie INC. | $88.83 | 2023-2025 | |
| Eisai INC. | $87.88 | 2023-2025 | |
| Celgene Corporation | $85.97 | 2025 | Reblozyl |
| Blueprint Medicines Corporation | $78.86 | 2025 | Ayvakit |
| Exelixis INC. | $71.38 | 2025 | Cabometyx |
| Janssen Biotech, INC. | $70.74 | 2024 | Darzalex, Imbruvica, Rybrevant |
| Beone Medicines USA, INC. | $68.02 | 2025 | Tevimbra, Brukinsa |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjan Goli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.